-
1دورية أكاديمية
المؤلفون: Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., Veronesi, G., Reck, M., Guidelines Committee, ESMO
المصدر: Hendriks , L E , Kerr , K M , Menis , J , Mok , T S , Nestle , U , Passaro , A , Peters , S , Planchard , D , Smit , E F , Solomon , B J , Veronesi , G , Reck , M , ESMO Guidelines Committee & Guidelines Committee , ESMO 2023 , ' Oncogene-addicted metastatic non-small-cell lung cancer : ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ' , Annals of Oncology , vol. 34 , no. 4 , pp. 339-357 . https://doi.org/10.1016/j.annonc.2022.12.009Test
مصطلحات موضوعية: ESCAT, ESMO Clinical Practice Guideline (CPG), ESMO-MCBS, oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC), treatment, targeted therapy, TYROSINE KINASE INHIBITORS, PROGRESSION-FREE SURVIVAL, RESPONSE EVALUATION CRITERIA, FACTOR RECEPTOR MUTATIONS, OPEN-LABEL, 1ST-LINE TREATMENT, SINGLE-ARM, TREATMENT-NAIVE, EGFR MUTATIONS, ADVANCED NSCLC
وصف الملف: application/pdf
العلاقة: https://cris.maastrichtuniversity.nl/en/publications/a6c20759-e209-411f-b9b7-789fc32e2f64Test
الإتاحة: https://doi.org/10.1016/j.annonc.2022.12.009Test
https://cris.maastrichtuniversity.nl/en/publications/a6c20759-e209-411f-b9b7-789fc32e2f64Test
https://cris.maastrichtuniversity.nl/ws/files/192165782/Hendriks-2023-Oncogene-addicted-metastatic-non-small.pdfTest -
2دورية أكاديمية
المؤلفون: Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Planchard, D., Peters, S., Smit, E. F., Solomon, B. J., Veronesi, G., Reck, M., Guidelines Committee, ESMO
المصدر: Hendriks , L E , Kerr , K M , Menis , J , Mok , T S , Nestle , U , Passaro , A , Planchard , D , Peters , S , Smit , E F , Solomon , B J , Veronesi , G , Reck , M , ESMO Guidelines Committee & Guidelines Committee , ESMO 2023 , ' Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ' , Annals of Oncology , vol. 34 , no. 4 , pp. 358-376 . https://doi.org/10.1016/j.annonc.2022.12.013Test
مصطلحات موضوعية: ESCAT, ESMO Clinical Practice Guideline (CPG), ESMO-MCBS, non-oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC), treatment, targeted therapy, immunotherapy, RANDOMIZED PHASE-III, QUALITY-OF-LIFE, PACLITAXEL DOUBLET CHEMOTHERAPY, RESPONSE EVALUATION CRITERIA, PLATINUM-BASED CHEMOTHERAPY, PEMETREXED PLUS CISPLATIN, SPECIFIED FINAL ANALYSIS, INDIVIDUAL PATIENT DATA, ELDERLY-PATIENTS, 2ND-LINE TREATMENT
وصف الملف: application/pdf
العلاقة: https://cris.maastrichtuniversity.nl/en/publications/7f71c7db-b119-4345-a38e-5b383cefe585Test
الإتاحة: https://doi.org/10.1016/j.annonc.2022.12.013Test
https://cris.maastrichtuniversity.nl/en/publications/7f71c7db-b119-4345-a38e-5b383cefe585Test
https://cris.maastrichtuniversity.nl/ws/files/192165470/Hendriks-2023-Non-oncogene-addicted-metastatic-non.pdfTest -
3دورية أكاديمية
المؤلفون: Gosney, J R, Paz-Ares, L, Jänne, P, Kerr, K M, Leighl, N B, Lozano, M D, Malapelle, U, Mok, T, Sheffield, B S, Tufman, A, Wistuba, I I, Peters, S
المساهمون: Gosney, J R, Paz-Ares, L, Jänne, P, Kerr, K M, Leighl, N B, Lozano, M D, Malapelle, U, Mok, T, Sheffield, B S, Tufman, A, Wistuba, I I, Peters, S
مصطلحات موضوعية: NSCLC, molecular pathology, non-small-cell lung cancer, predictive biomarker, reflex testing, turnaround time
الوصف: Biomarker tests in lung cancer have been traditionally ordered by the treating oncologist upon confirmation of an appropriate pathological diagnosis. The delay this introduces prolongs yet further what is already a complex, multi-stage, pre-treatment pathway and delays the start of first-line systemic treatment, which is crucially informed by the results of such analysis. Reflex testing, in which the responsibility for testing for an agreed range of biomarkers lies with the pathologist, has been shown to standardise and expedite the process. Twelve experts discussed the rationale and considerations for implementing reflex testing as standard clinical practice.
العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:001040711700001; volume:8; issue:4; firstpage:101587; journal:ESMO OPEN; https://hdl.handle.net/11588/929064Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85162976928
-
4دورية أكاديمية
المؤلفون: Letovanec I., Finn S., Zygoura P., Smyth P., Soltermann A., Bubendorf L., Speel E. -J. M., Marchetti A., Nonaka D., Monkhorst K., Hager H., Martorell M., Sejda A., Cheney R., Hernandez-Losa J., Verbeken E., Weder W., Savic S., Di Lorito A., Navarro A., Felip E., Warth A., Baas P., Meldgaard P., Blackhall F., Dingemans A. -M., Dienemann H., Dziadziuszko R., Vansteenkiste J., O'Brien C., Geiger T., Sherlock J., Schageman J., Dafni U., Kammler R., Kerr K. M., Thunnissen E., Stahel R. A., Peters S., Rosell R., Molina M. A., Hiltbrunner A., Marti N., Tsourti Z., Polydoropoulou V., Gray S., Opitz I., Curioni A., Lardinois D., Ruland A., De Luca G.
المساهمون: Letovanec, I., Finn, S., Zygoura, P., Smyth, P., Soltermann, A., Bubendorf, L., Speel, E. -J. M., Marchetti, A., Nonaka, D., Monkhorst, K., Hager, H., Martorell, M., Sejda, A., Cheney, R., Hernandez-Losa, J., Verbeken, E., Weder, W., Savic, S., Di Lorito, A., Navarro, A., Felip, E., Warth, A., Baas, P., Meldgaard, P., Blackhall, F., Dingemans, A. -M., Dienemann, H., Dziadziuszko, R., Vansteenkiste, J., O'Brien, C., Geiger, T., Sherlock, J., Schageman, J., Dafni, U., Kammler, R., Kerr, K. M., Thunnissen, E., Stahel, R. A., Peters, S., Rosell, R., Molina, M. A., Hiltbrunner, A., Marti, N., Tsourti, Z., Polydoropoulou, V., Gray, S., Opitz, I., Curioni, A., Lardinois, D., Ruland, A., De Luca, G.
مصطلحات موضوعية: ALK, NGS, NSCLC, RT-PCR, Anaplastic Lymphoma Kinase, Carcinoma, Non-Small-Cell Lung, Cohort Studie, Europe, Female, High-Throughput Nucleotide Sequencing, Human, Lung Neoplasm, Male, Reverse Transcriptase Polymerase Chain Reaction, Thoracic Neoplasms
الوصف: Introduction: The reported prevalence of ALK receptor tyrosine kinase gene (ALK) rearrangement in NSCLC ranges from 2% to 7%. The primary standard diagnostic method is fluorescence in situ hybridization (FISH). Recently, immunohistochemistry (IHC) has also proved to be a reproducible and sensitive technique. Reverse-transcriptase polymerase chain reaction (RT-PCR) has also been advocated, and most recently, the advent of targeted next-generation sequencing (NGS) for ALK and other fusions has become possible. This study compares anaplastic lymphoma kinase (ALK) evaluation with all four techniques in resected NSCLC from the large European Thoracic Oncology Platform Lungscape cohort. Methods: A total of 96 cases from the European Thoracic Oncology Platform Lungscape iBiobank, with any ALK immunoreactivity were examined by FISH, central RT-PCR, and NGS. An H-score higher than 120 defines IHC positivity. RNA was extracted from the same formalin-fixed, paraffin-embedded tissues. For RT-PCR, primers covered the most frequent ALK translocations. For NGS, the Oncomine Solid Tumour Fusion Transcript Kit (Thermo Fisher Scientific, Waltham, MA) was used. The concordance was assessed using the Cohen kappa coefficient (two-sided alpha < 5%). Results: NGS provided results for 77 of the 95 cases tested (81.1%), whereas RT-PCR provided results for 77 of 96 (80.2%). Concordance occurred in 55 cases of the 60 cases tested with all four methods (43 ALK negative and 12 ALK positive). Using ALK copositivity for IHC and FISH as the criterion standard, we derived a sensitivity for RT-PCR/NGS of 70.0%/85.0%, with a specificity of 87.1%/79.0%. When either RT-PCR or NGS was combined with IHC, the sensitivity remained the same, whereas the specificity increased to 88.7% and 83.9% respectively. Conclusion: NGS evaluation with the Oncomine Solid Tumour Fusion transcript kit and RT-PCR proved to have high sensitivity and specificity, advocating their use in routine practice. For maximal sensitivity and specificity, ALK status should be ...
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/29191776; info:eu-repo/semantics/altIdentifier/wos/WOS:000429213700021; volume:13; issue:3; firstpage:413; lastpage:425; numberofpages:13; journal:JOURNAL OF THORACIC ONCOLOGY; http://hdl.handle.net/11564/712077Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85041242224; https://www.journals.elsevier.com/journal-of-thoracic-oncologyTest/
الإتاحة: https://doi.org/10.1016/j.jtho.2017.11.117Test
http://hdl.handle.net/11564/712077Test
https://www.journals.elsevier.com/journal-of-thoracic-oncologyTest/ -
5دورية أكاديمية
المؤلفون: Al Bakir, M., Huebner, A., Martinez-Ruiz, C., Grigoriadis, K., Watkins, T. B. K., Pich, O., Moore, D. A., Veeriah, S., Ward, S., Laycock, J., Johnson, D., Rowan, A., Razaq, M., Akther, M., Naceur-Lombardelli, C., Prymas, P., Toncheva, A., Hessey, S., Dietzen, M., Colliver, E., Frankell, A. M., Bunkum, A., Lim, E. L., Karasaki, T., Abbosh, C., Hiley, C. T., Hill, M. S., Cook, D. E., Wilson, G. A., Salgado, R., Nye, E., Stone, R. K., Fennell, D. A., Price, G., Kerr, K. M., Naidu, B., Middleton, G., Summers, Yvonne J, Lindsay, Colin R, Blackhall, Fiona H, Cave, J., Blyth, K. G., Nair, A., Ahmed, A., Taylor, M. N., Procter, A. J., Falzon, M., Lawrence, D., Navani, N., Thakrar, R. M., Janes, S. M., Papadatos-Pastos, D., Forster, M. D., Lee, S. M., Ahmad, T., Quezada, S. A., Peggs, K. S., Van Loo, P., Dive, Caroline, Hackshaw, A., Birkbak, N. J., Zaccaria, S., Jamal-Hanjani, M., McGranahan, N., Swanton, C., Lester, J. F., Bajaj, A., Nakas, A., Sodha-Ramdeen, A., Ang, K., Tufail, M., Chowdhry, M. F., Scotland, M., Boyles, R., Rathinam, S., Wilson, C., Marrone, D., Dulloo, S., Matharu, G., Shaw, J. A., Riley, J., Primrose, L., Boleti, E., Cheyne, H., Khalil, M., Richardson, S., Cruickshank, T., Benafif, S., Gilbert, K., Patel, A. J., Osman, A., Lacson, C., Langman, G., Shackleford, H., Djearaman, M., Kadiri, S., Leek, A., Hodgkinson, J. D., Totten, N., Montero, A., Smith, E., Fontaine, E., Granato, F., Doran, H., Novasio, J., Rammohan, K., Joseph, L., Bishop, P., Shah, R., Moss, S., Joshi, V., Crosbie, P., Gomes, F., Brown, K., Carter, M., Chaturvedi, A., Priest, L., Oliveira, P., Krebs, M. G., Clipson, A., Tugwood, J., Kerr, A., Rothwell, D. G., Kilgour, E., Aerts, H., Schwarz, R. F., Kaufmann, T. L., Rosenthal, R., Szallasi, Z., Kisistok, J., Sokac, M., Diossy, M., Demeulemeester, J., Stewart, A., Magness, A., Karamani, A., Chain, B., Campbell, B. B., Castignani, C., Bailey, C., Puttick, C., Weeden, C. E., Lee, C., Richard, C., Pearce, D. R., Karagianni, D., Biswas, D., Levi, D., Hoxha, E., Cadieux, E. L., Gronroos, E., Galvez-Cancino, F., Athanasopoulou, F., Gimeno-Valiente, F., Kassiotis, G., Stavrou, G., Mastrokalos, G., Zhai, H. R., Lowe, H. L., Matos, I., Goldman, J., Reading, J. L., Black, J. R. M., Herrero, J., Rane, J. K., Nicod, J., Lam, J. M., Hartley, J. A., Enfield, K. S. S., Selvaraju, K., Thol, K., Litchfield, K., Ng, K. W., Chen, K. Z., Dijkstra, K., Thakkar, K., Ensell, L., Shah, M., Vasquez, M., Litovchenko, M., Sunderland, M. W., Leung, M., Escudero, M., Angelova, M., Tanic, M., Sivakumar, M., Kanu, N., Chervova, O., Lucas, O., Al-Sawaf, O., Hobson, P., Pawlik, P., Bentham, R., Hynds, R. E., Vendramin, R., Saghafinia, S., Lopez, S., Gamble, S., Ung, S. K. A., Vanloo, S., Boeing, S., Beck, S., Bola, S. K., Denner, T., Marafioti, T., Mourikis, T. P., Spanswick, V., Barbe, V., Lu, W. T., Hill, W., Liu, W. K., Wu, Y., Naito, Y., Ramsden, Z., Veiga, C., Royle, G., Collins-Fekete, C. A., Fraioli, F., Ashford, P., Clark, T., Borg, E., Wilson, J., Patrini, D., Hoogenboom, E. M., Monk, F., Holding, J. W., Choudhary, J., Bhakhri, K., Scarci, M., Hayward, M., Panagiotopoulos, N., Gorman, P., Khiroya, R., Stephens, R. C. M., Wong, Y. N. S., Bandula, S., Sharp, A., Smith, S., Gower, N., Dhanda, H. K., Chan, K., Pilotti, C., Leslie, R., Grapa, A., Zhang, H. Y., AbdulJabbar, K., Pan, X. X., Yuan, Y. Y., Chuter, D., MacKenzie, M., Chee, S., Alzetani, A., Scarlett, L., Richards, J., Ingram, P., Austin, S., Lim, E., De Sousa, P., Jordan, S., Rice, A., Raubenheimer, H., Bhayani, H., Ambrose, L., Devaraj, A., Chavan, H., Begum, S., Buderi, S. I., Kaniu, D., Malima, M., Booth, S., Nicholson, A. G., Fernandes, N., Shah, P., Proli, C., Hewish, M., Danson, S., Shackcloth, M. J., Robinson, L., Russell, P., Dick, C., Le Quesne, J., Kirk, A., Asif, M., Bilancia, R., Kostoulas, N., Thomas, M.
المساهمون: Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London
الوصف: Metastatic disease is responsible for the majority of cancer-related deaths1. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 non-metastatic tumours. In 25% of cases, metastases diverged early, before the last clonal sweep in the primary tumour, and early divergence was enriched for patients who were smokers at the time of initial diagnosis. Simulations suggested that early metastatic divergence more frequently occurred at smaller tumour diameters (less than 8 mm). Single-region primary tumour sampling resulted in 83% of late divergence cases being misclassified as early, highlighting the importance of extensive primary tumour sampling. Polyclonal dissemination, which was associated with extrathoracic disease recurrence, was found in 32% of cases. Primary lymph node disease contributed to metastatic relapse in less than 20% of cases, representing a hallmark of metastatic potential rather than a route to subsequent recurrences/disease progression. Metastasis-seeding subclones exhibited subclonal expansions within primary tumours, probably reflecting positive selection. Our findings highlight the importance of selection in metastatic clone evolution within untreated primary tumours, the distinction between monoclonal versus polyclonal seeding in dictating site of recurrence, the limitations of current radiological screening approaches for early diverging tumours and the need to develop strategies to target metastasis-seeding subclones before relapse.
العلاقة: https://dx.doi.org/10.1038/s41586-023-05729-xTest; Al Bakir M, Huebner A, Martinez-Ruiz C, Grigoriadis K, Watkins TBK, Pich O, et al. The evolution of non-small cell lung cancer metastases in TRACERx. Nature. 2023 2023 Apr. PubMed PMID: WOS:000991048500004.; http://hdl.handle.net/10541/626391Test; Nature
-
6دورية أكاديمية
المؤلفون: Frankell, A. M., Dietzen, M., Al Bakir, M., Lim, E. L., Karasaki, T., Ward, S., Veeriah, S., Colliver, E., Huebner, A., Bunkum, A., Hill, M. S., Grigoriadis, K., Moore, D. A., Black, J. R. M., Liu, W. K., Thol, K., Pich, O., Watkins, T. B. K., Naceur-Lombardelli, C., Cook, D. E., Salgado, R., Wilson, G. A., Bailey, C., Angelova, M., Bentham, R., Martínez-Ruiz, C., Abbosh, C., Nicholson, A. G., Le Quesne, J., Biswas, D., Rosenthal, R., Puttick, C., Hessey, S., Lee, C., Prymas, P., Toncheva, A., Smith, J., Xing, W., Nicod, J., Price, G., Kerr, K. M., Naidu, B., Middleton, G., Blyth, K. G., Fennell, D. A., Forster, M. D., Lee, S. M., Falzon, M., Hewish, M., Shackcloth, M. J., Lim, E., Benafif, S., Russell, P., Boleti, E., Krebs, Matthew G, Lester, J. F., Papadatos-Pastos, D., Ahmad, T., Thakrar, R. M., Lawrence, D., Navani, N., Janes, S. M., Dive, Caroline, Blackhall, Fiona H, Summers, Yvonne J, Cave, J., Marafioti, T., Herrero, J., Quezada, S. A., Peggs, K. S., Schwarz, R. F., Van Loo, P., Miedema, D. M., Birkbak, N. J., Hiley, C. T., Hackshaw, A., Zaccaria, S., Jamal-Hanjani, M., McGranahan, N., Swanton, C.
المساهمون: Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK
الوصف: Lung cancer is the leading cause of cancer-associated mortality worldwide1. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer genes were under significant subclonal selection, including classical tumour initiators such as TP53 and KRAS. We defined evolutionary dependencies between drivers, mutational processes and whole genome doubling (WGD) events. Despite patients having a history of smoking, 8% of lung adenocarcinomas lacked evidence of tobacco-induced mutagenesis. These tumours also had similar detection rates for EGFR mutations and for RET, ROS1, ALK and MET oncogenic isoforms compared with tumours in never-smokers, which suggests that they have a similar aetiology and pathogenesis. Large subclonal expansions were associated with positive subclonal selection. Patients with tumours harbouring recent subclonal expansions, on the terminus of a phylogenetic branch, had significantly shorter disease-free survival. Subclonal WGD was detected in 19% of tumours, and 10% of tumours harboured multiple subclonal WGDs in parallel. Subclonal, but not truncal, WGD was associated with shorter disease-free survival. Copy number heterogeneity was associated with extrathoracic relapse within 1 year after surgery. These data demonstrate the importance of clonal expansion, WGD and copy number instability in determining the timing and patterns of relapse in non-small cell lung cancer and provide a comprehensive clinical cancer evolutionary data resource.
العلاقة: https://dx.doi.org/10.1038/s41586-023-05783-5Test; Frankell AM, Dietzen M, Al Bakir M, Lim EL, Karasaki T, Ward S, et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature. 2023 Apr;616(7957):525-33. PubMed PMID: 37046096. Pubmed Central PMCID: PMC10115649 for tumour monitoring (PCT/EP2022/077987). M.A.B. has consulted for Achilles Therapeutics. D.A.M. reports speaker fees from AstraZeneca, Eli Lilly and Takeda, consultancy fees from AstraZeneca, Thermo Fisher, Takeda, Amgen, Janssen, MIM Software, Bristol-Myers Squibb (BMS) and Eli Lilly and has received educational support from Takeda and Amgen. S.V. is a co-inventor on a patent to detect molecules in a sample (US patent 10578620). G.A.W. is employed by and has stock options in Achilles Therapeutics. R.S. reports non-financial support from Merck and BMS, research support from Merck, Puma Biotechnology and Roche, and personal fees from Roche, BMS and Exact Sciences for advisory boards. C.A. has received speaking honoraria or expenses from Novartis, Roche, AstraZeneca and BMS and reports employment at AstraZeneca. C.A. is an inventor on a European patent application relating to assay technology to detect tumour recurrence (PCT/GB2017/053289); the patent has been licensed to commercial entities and under their terms of employment, C.A. is due a revenue share of any revenue generated from such licence(s). C.A. declares a patent application (PCT/US2017/028013) for methods to detect lung cancer. C.A. is a named inventor on a patent application to determine methods and systems for tumour monitoring (PCT/EP2022/077987). C.A. is a named inventor on a provisional patent protection related to a ctDNA detection algorithm. D.B. reports personal fees from NanoString and AstraZeneca. He has a patent (PCT/GB2020/050221) issued on methods for cancer prognostication. R.R. is an employee of and has stock options in Achilles Therapeutics and holds a European patent on targeting neoantigens (PCT/EP2016/059401) and in determining HLA LOH (PCT/GB2018/052004). D.A.F. reports grants from Aldeyra, Boehringer Ingelheim, Astex Therapeutics, Bayer, BMS, GSK, RS Oncology, Clovis, Eli Lilly, MSD, GSK, personal fees from Atara, BMS, Boehringer Ingelheim, Cambridge Clinical Laboratories, Targovax, Roche and RS Oncology. M.D.F. acknowledges grant support from CRUK, AstraZeneca, Boehringer Ingelheim, MSD and Merck; is an advisory board member for Transgene; and has consulted for Achilles, Amgen, AstraZeneca, Bayer, Boxer, BMS, Celgene, EQRx, Guardant Health, Immutep, Ixogen, Janssen, Merck, MSD, Nanobiotix, Novartis, Oxford VacMedix, Pharmamar, Pfizer, Roche, Takeda and UltraHuman. K.S.P. is a co-founder of Achilles Therapeutics. S.A.Q. is a co-founder, stockholder and Chief Scientific Officer of Achilles Therapeutics. E.L. has received funding from AstraZeneca, Boehringer Ingelheim, Medela, Johnson & Johnson/Ethicon, Covidien/Medtronic, Guardant Health, Takeda, Lilly Oncology, Boehringer Ingelheim and Bayer. E.L. has received consulting fees from Beigene, Roche and BMS, honoraria from Medela and is a founder My Cancer Companion, Healthcare Companion Ltd. N.N. reports honoraria for non-promotional educational talks, advisory boards or conference attendance from Amgen, AstraZeneca, Boehringer Ingelheim, BMS, Fujifilm, Guardant Health, Intuitive, Janssen, Lilly, Merck Sharp & Dohme, Olympus, OncLive, PeerVoice, Pfizer and Takeda. S.M.J. has received fees for advisory board membership in the past 3 years from AstraZeneca, Bard1 Lifescience and Johnson & Johnson. He has received a grant income from Owlstone and GRAIL Inc. He has received assistance with travel to an academic meeting from Cheisi. C.D. has received research funding and educational research grants from AstraZeneca, Astex Pharmaceuticals, Bioven, Amgen, Carrick Therapeutics, Merck, Taiho Oncology, GSK, Bayer, Boehringer Ingelheim, Roche, BMS, Novartis, Celgene, Epigene Therapeutics, Angle PLC, Menarini, Clearbridge Biomedics, Thermo Fisher Scientific and Neomed Therapeutics. C.D. has also received honoraria for consultancy and/or advisory boards from Biocartis, Merck, AstraZeneca, GRAIL and Boehringer Ingelheim. J.C. reports funding from Amgen to attend a conference. A. Hackshaw has received fees for being a member of Independent Data Monitoring Committees for Roche-sponsored clinical trials, and academic projects co-ordinated by Roche. N.J.B. is a co-inventor on a patent to identify responders to cancer treatment (PCT/GB2018/051912), has a patent application (PCT/GB2020/050221) on methods for cancer prognostication and is a co-inventor on a patent for methods for predicting anticancer responses (US14/466,208). C.T.H. has received speaker fees from AstraZeneca. M.J.-H. has consulted for and is a member of the Achilles Therapeutics Scientific Advisory Board (SAB) and Steering Committee, has received speaker honoraria from Pfizer, Astex Pharmaceuticals, Oslo Cancer Cluster, and holds a patent (PCT/US2017/028013) relating to methods for lung cancer detection. This patent has been licensed to commercial entities and under terms of employment, M.J.-H. is due a share of any revenue generated from such licence(s). N.M. has received consultancy fees and has stock options in Achilles Therapeutics. N.M. holds European patents relating to targeting neoantigens (PCT/EP2016/059401), identifying patient response to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004) and predicting survival rates of patients with cancer (PCT/GB2020/050221). C.S. acknowledges grant support from AstraZeneca, Boehringer-Ingelheim, BMS, Pfizer, Roche-Ventana, Invitae (previously Archer Dx (collaboration in minimal residual disease sequencing technologies)) and Ono Pharmaceutical. C.S. is an AstraZeneca Advisory Board member and Chief Investigator for the AZ MeRmaiD 1 and 2 clinical trials and is also Co-Chief Investigator of the NHS Galleri trial funded by GRAIL and a paid member of GRAIL’s SAB. He receives consultant fees from Achilles Therapeutics (also a SAB member), Bicycle Therapeutics (also a SAB member), Genentech, Medicxi, Roche Innovation Centre–Shanghai, Metabomed (until July 2022), and the Sarah Cannon Research Institute. C.S. had stock options in Apogen Biotechnologies and GRAIL until June 2021, and currently has stock options in Epic Bioscience, Bicycle Therapeutics, and has stock options and is co-founder of Achilles Therapeutics. C.S. is an inventor on a European patent application relating to an assay technology to detect tumour recurrence (PCT/GB2017/053289), the patent has been licensed to commercial entities and under his terms of employment, C.S. is due a revenue share of any revenue generated from such licence(s). C.S. holds patents relating to targeting neoantigens (PCT/EP2016/059401), identifying patient responses to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221), identifying patients who respond to cancer treatment (PCT/GB2018/051912), a US patent relating to detecting tumour mutations (PCT/US2017/28013), methods for lung cancer detection (US20190106751A1) and both a European and US patent related to identifying indel mutation targets (PCT/GB2018/051892) and is a co-inventor on a patent application to determine methods and systems for tumour monitoring (PCT/EP2022/077987). C.S. is a named inventor on a provisional patent related to a ctDNA detection algorithm. Epub 2023/04/13. eng.; http://hdl.handle.net/10541/626225Test; Nature
-
7دورية أكاديمية
المؤلفون: Kerr, K M, Dafni, U, Schulze, K, Thunnissen, E, Bubendorf, L, Hager, H, Finn, S, Biernat, W, Vliegen, L, Losa, J H, Marchetti, A, Cheney, R, Warth, A, Speel, Ernst-Jan, Blackhall, F, Monkhorst, K, Jantus Lewintre, E, Tischler, V, Clark, C, Bertran-Alamillo, J, Meldgaard, P, Gately, K, Wrona, A, Vandenberghe, P, Felip, E, De Luca, G, Savic, S, Muley, T, Smit, E F, Dingemans, A-M C, Priest, L, Baas, P, Camps, C, Weder, W, Polydoropoulou, V, Geiger, T R, Kammler, R, Sumiyoshi, T, Molina, M A, Shames, D S, Stahel, R A, Peters, S
المصدر: Kerr , K M , Dafni , U , Schulze , K , Thunnissen , E , Bubendorf , L , Hager , H , Finn , S , Biernat , W , Vliegen , L , Losa , J H , Marchetti , A , Cheney , R , Warth , A , Speel , E-J , Blackhall , F , Monkhorst , K , Jantus Lewintre , E , Tischler , V , Clark , C , Bertran-Alamillo , J , Meldgaard , P , Gately , K , Wrona , A , Vandenberghe , P , ....
الوصف: Background: Reported prevalence of driver gene mutations in non-small cell lung cancer (NSCLC) is highly variable and clinical correlations are emerging. Using NSCLC biomaterial and clinical data from the ETOP Lungscape iBiobank, we explore the epidemiology of mutations and association to clinicopathological features and patient outcome (relapse-free survival, time-to-relapse, overall survival). Methods: Clinically-annotated, resected stage I-III NSCLC FFPE tissue was assessed for gene mutation using a microfluidics-based multiplex PCR platform. Mutant-allele detection sensitivity is > 1% for most of the ∼150 (13 genes) mutations covered in the multiplex test. Results: Multiplex testing has been performed in 2063 (76.2%) of the 2709 Lungscape cases (median follow-up 4.8 years). FFPE samples mostly date from 2005-8, yet recently extracted DNA quality and quantity was generally good. Average DNA yield/case was 2.63µg; 38 cases (1.4%) failed QC and were excluded from study. 95.1% of included cases allowed the complete panel of mutations to be tested. Most common were KRAS, MET, EGFR and PIK3CA mutations with overall prevalence of 23.0%, 6.8%, 5.4% and 4.9% respectively. KRAS and EGFR mutations were significantly more frequent in adenocarcinomas: PIK3CA in squamous cell carcinomas. MET mutation prevalence did not differ between histology groups. EGFR mutations were found predominantly in never smokers; KRAS in current/former smokers. For all the above mutations, there was no difference in outcome between mutated and non-mutated cases. Conclusion: Archival FFPE NSCLC material is adequate for multiplex mutation analysis. In this large, predominantly European, clinically-annotated stage I-III NSCLC cohort, none of the mutations characterized showed prognostic significance.
الإتاحة: https://doi.org/10.1093/annonc/mdx629Test
https://research.vumc.nl/en/publications/2bf59980-0a5a-4fa9-ab3f-c4c706300e92Test -
8دورية أكاديمية
المؤلفون: Williams, G. H., Nicholson, A. G., Snead, D. R.J., Thunnissen, E., Lantuejoul, S., Cane, P., Kerr, K. M., Loddo, M., Scott, M., Scorer, P. W., Barker, C.
المصدر: Williams , G H , Nicholson , A G , Snead , D R J , Thunnissen , E , Lantuejoul , S , Cane , P , Kerr , K M , Loddo , M , Scott , M , Scorer , P W & Barker , C 2018 , ' Inter-rater reliability of programmed death ligand 1 (PD-L1) scoring using the VENTANA PD-L1 (SP263) assay in non-small cell lung cancer (NSCLC) ' , Annals of oncology : official journal of the European Society for Medical Oncology , vol. 29 , pp. viii49 . https://doi.org/10.1093/annonc/mdy269.153Test
الإتاحة: https://doi.org/10.1093/annonc/mdy269.153Test
https://research.vumc.nl/en/publications/50d27b52-8fd5-40bf-936f-d0727df8cc3aTest
http://www.scopus.com/inward/record.url?scp=85081531174&partnerID=8YFLogxKTest -
9دورية أكاديمية
المؤلفون: Woolhouse, I., Bishop, L., Darlison, Liz, de Fonseka, D., Edey, A., Edwards, J., Faivre-Finn, C., Fennell, Dean A., Holmes, S., Kerr, K. M., Nakas, Apostolos, Peel, T., Rahman, N. M., Slade, M., Steele, J., Tsim, S., Maskell, N. A.
مصطلحات موضوعية: mesothelioma
الوصف: The full guideline for the investigation and management of malignant pleural mesothelioma is published inThorax. The following is a summary of the recommendations and good practice points. The sections referred to in the summary refer to the full guideline. ; Peer-reviewed ; Publisher Version
العلاقة: https://www.ncbi.nlm.nih.gov/pubmed/29531746Test; BMJ Open Respiratory Research, 2018, 5 (1), e000266; http://bmjopenrespres.bmj.com/content/5/1/e000266.infoTest; http://hdl.handle.net/2381/41514Test; bmjresp-2017-000266
الإتاحة: https://doi.org/10.1136/bmjresp-2017-000266Test
http://bmjopenrespres.bmj.com/content/5/1/e000266.infoTest
http://hdl.handle.net/2381/41514Test -
10دورية أكاديمية
المؤلفون: Bonomi, P D, Gandara, D, Hirsch, F R, Kerr, K M, Obasaju, C, Paz Ares, Luis Gonzaga, Bellomo, C, Bradley, J D, Bunn, P A, Culligan, M, Jett, J R, Kim, E S, Langer, C J, Natale, R B, Novello, S, Pérol, M, Ramalingam, S S, Reck, M, Reynolds, C H, Smit, E F, Socinski, M A, Spigel, D R, Vansteenkiste, J F, Wakelee, H, Thatcher, N
المساهمون: Fundación Lilly
مصطلحات موضوعية: GROWTH-FACTOR RECEPTOR, PHASE-III TRIAL, CLINICAL-PRACTICE GUIDELINES, CISPLATIN PLUS GEMCITABINE, OPEN-LABEL, STAGE IV, 1ST-LINE THERAPY, FOLLOW-UP, CETUXIMAB, CHEMOTHERAPY
الوصف: The concept of predictive biomarkers for EGFR-directed mAbs addressed in this article were originally discussed at a meeting convened by Eli Lilly and Company that covered topics for physician education on SqCLC, for which participants, includ- ing some of the authors on this publication, received an honor- arium. This publication was developed separately from the meeting, and the authors received no payment in relation to the development of this publication. The authors would like to thank Charlene Rivera, PhD and Rob Kite, BSc (Hons), at Complete HealthVizion for assistance with writing and revising the draft manuscript on the basis of detailed feedback from all authors. Primary responsibility for the opinions, conclusions, and interpretation of data lay with the authors, and all authors approved the final version of the manuscript. ; Background: Upregulated expression and aberrant activation of the epidermal growth-factor receptor (EGFR) are found in lung cancer, making EGFR a relevant target for non-small-cell lung cancer (NSCLC). Treatment with anti-EGFR monoclonal antibodies (mAbs) is associated with modest improvement in overall survival in patients with squamous cell lung cancer (SqCLC) who have a significant unmet need for effective treatment options. While there is evidence that using EGFR gene copy number, EGFR mutation, and EGFR protein expression as biomarkers can help select patients who respond to treatment, it is important to consider biomarkers for response in patients treated with combination therapies that include EGFR mAbs. Design: Randomized trials of EGFR-directed mAbs cetuximab and necitumumab in combination with chemotherapy, immunotherapy, or antiangiogenic therapy in patients with advanced NSCLC, including SqCLC, were searched in the literature. Results of associations of potential biomarkers and outcomes were summarized. Results: Data from phase III clinical trials indicate that patients with NSCLC, including SqCLC, whose tumors express high levels of EGFR protein (H-score of ≥200) ...
العلاقة: https://doi.org/10.1093/annonc/mdy196Test.; Ann Oncol. 2018; 29(8):1701-1709.; http://hdl.handle.net/20.500.12105/6820Test; Annals of oncology : official journal of the European Society for Medical Oncology
الإتاحة: https://doi.org/20.500.12105/6820Test
https://doi.org/10.1093/annonc/mdy196Test
https://hdl.handle.net/20.500.12105/6820Test
النص الكامل